Polaris Oncology Survivor Transition (POST) System (POST)

November 22, 2019 updated by: Polaris Health Directions

The POST's public health impact is likely to be substantial because it will improve cancer survivorship planning, which is currently an important deficiency in cancer care recognized by the Institute of Medicine and the American College of Surgeons.

The POST may have many potential benefits for patients such as:

  1. improved long-term health outcomes;
  2. improved psychosocial outcomes and quality of life;
  3. smoother transitions back into old and new life roles; and
  4. improved continuity and coordination of care between providers.

Most importantly, the POST's influence may reach beyond the patients it directly serves as it could help scientists and health care providers understand the potential benefits of cancer survivorship planning and how to best design and implement survivorship planning when patients are ending treatment for cancer.

Study Overview

Status

Completed

Conditions

Detailed Description

By January 2015, oncology care providers will be expected to craft Survivorship Care Plans (SCPs) for all individuals ending active treatment for cancer; however, there is a lack of systematic study of the impact survivorship planning has on patients, providers, or healthcare systems. The Polaris Oncology Survivorship Transition (POST) program is a web-based system that incorporates recommendations from the Institute of Medicine (IOM) and American College of Surgeons (ACS) to assist with cancer survivorship planning. It is a patient-centered approach that integrates input from both the treating oncology team and the patient. Phase 1 built and iteratively modified (N=25) the POST system and Phase 2 will test whether the SCPs impact patient and provider outcomes using a single blind, randomized controlled trial (RCT). Breast cancer patients (n=230) transitioning out of active treatment will be recruited and randomly assigned to receive Treatment as Usual (n=115) or the POST (n=115). All participants will be assessed at 1, 3, and 6 months by a research assistant blind to baseline status and group assignment. Primary outcomes will include quality of life, mechanisms of action such as confidence in entering survivorship, and other outcomes such as (1) depression and anxiety, (2) adherence to medical and behavioral health recommendations, (3) health care utilization, and (4) patient and provider satisfaction with the POST system.The POST will innovate the clinical setting through being the first system to produce computer generated tailored survivorship plans fully reflecting IOM recommendations and the new ACS 2015 requirements; incorporating information from both the oncology provider and the patient; featuring readily available "plug in" for two-way electronic health record integration; providing dynamic, electronic referrals for specialized support services; and facilitating care coordination between the oncologist and PCP. This study's impact will be significant. If hypotheses are confirmed, clear scientific evidence will exist for supporting survivorship care planning into oncology clinical practice. If hypotheses are disconfirmed, important lessons will guide future directions for care planning, including whether failure to affect outcomes was due to failure to impact several hypothesized mechanisms of action.

Study Type

Interventional

Enrollment (Actual)

200

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Worcester, Massachusetts, United States, 01655
        • University of Massachusetts Medical School-Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • 18 years or older
  • Confirmed diagnosis of breast cancer (not metastatic)
  • A final active treatment appointment scheduled with oncology team
  • Able to read or understand English at a 6th grade level

Exclusion Criteria:

  • Altered mental status (e.g., psychosis, delirium, disorientation)
  • Visual problems preventing them from reading the assessment and reports
  • Severe illness that would preclude conversation or interface with a computer (e.g.,persistent nausea/vomiting, severe pain)
  • Unable to read or understand English at a 6th grade level
  • Characteristics that would prevent adequate follow-up (e.g., lack of a telephone)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: POST SCP
Patient receives Survivorship Care Plan (SCP) after active treatment ends. It will be discussed with the patient. SCP includes medical and psychosocial history, medical contact information, 5-year follow-up plan and educational materials.
POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.
Active Comparator: POST TAU
Patient receives treatment as usual (TAU) after active treatment ends.
The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Quality of Life
Time Frame: 1,3, 6 months after entering the study
Quality of life will be measured at baseline and at the follow-ups using the City of Hope Quality of Life measure. Improvement in quality of life is the primary goal of survivorship planning.
1,3, 6 months after entering the study

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Confidence in Transitioning to Survivorship
Time Frame: 1,3,6 months after entering the study
National Cancer Institute (NCI) and the Institute of Medicine (IOM) have emphasized that SCPs should help improve patients' feelings of preparedness and confidence in managing and understanding the next steps at the end of treatment. This will be measured at baseline and follow-up sessions using the Confidence in Survivorship Information Questionnaire (CSI).
1,3,6 months after entering the study
Changes in Depression
Time Frame: 1,3,6 months after entering study
Changes in depression will be measured by the Patient Health Questionnaire -9 (PHQ-9).
1,3,6 months after entering study
Changes in Anxiety
Time Frame: 1,3,6 months after entering study
Changes in anxiety will be measured by the General Anxiety Disorder 7-item measure (GAD-7).
1,3,6 months after entering study
Change in Health care utilization
Time Frame: 6-months after entering the study
Participants' medical charts will be reviewed six months after termination of active treatment for frequency and appropriateness of oncology, primary care, and emergency room visits, as well as hospitalizations.
6-months after entering the study
Change in Patient Satisfaction and Usefulness of SCP
Time Frame: 1,3,6 months after entering the study
Patients will be asked to assess their satisfaction with the POST program and with the content and quality of the SCP.
1,3,6 months after entering the study
Change in Patient Satisfaction with the POST system
Time Frame: 1,3,6 months after entering the study
Patients will be asked to assess their satisfaction with the POST system.
1,3,6 months after entering the study
Change in Provider Satisfaction with the POST system
Time Frame: 1,3,6 months after entering the study
Providers will be asked to assess their satisfaction with the POST system.
1,3,6 months after entering the study

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Erin O'Hea, PhD, University of Massachusetts, Worcester

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 30, 2016

Primary Completion (Actual)

December 31, 2018

Study Completion (Actual)

August 31, 2019

Study Registration Dates

First Submitted

December 16, 2015

First Submitted That Met QC Criteria

December 17, 2015

First Posted (Estimate)

December 22, 2015

Study Record Updates

Last Update Posted (Actual)

November 26, 2019

Last Update Submitted That Met QC Criteria

November 22, 2019

Last Verified

November 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 2R42CA174048-03 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on POST Intervention

3
Subscribe